Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression
暂无分享,去创建一个
[1] M. Karin. Nuclear factor-κB in cancer development and progression , 2006, Nature.
[2] Wanjun Chen. Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. , 2006, Frontiers in bioscience : a journal and virtual library.
[3] M. Karin. Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.
[4] C. Casciani,et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression , 1996, Cancer Immunology, Immunotherapy.
[5] L. Coussens,et al. Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.
[6] J. Nyhus,et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. , 2002, Cancer research.
[7] J. Fung,et al. De novo malignancies after liver transplantation: A major cause of late death , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[8] S. Cingarlini,et al. Derangement of immune responses by myeloid suppressor cells , 2004, Cancer Immunology, Immunotherapy.
[9] I. Penn. Posttransplant malignancies , 2004, World Journal of Urology.
[10] Michael Karin,et al. NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.
[11] P. Allavena,et al. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. , 2004, European journal of cancer.
[12] Autoantibodies, autoimmunity and cancer (review). , 1998, Oncology reports.
[13] B. Morton,et al. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. , 1986, Cancer research.
[14] J. Ceuppens,et al. Regulation of the immune response by prostaglandins , 1983, Journal of Clinical Immunology.
[15] J. Myśliwska,et al. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. , 2004, Clinical immunology.
[16] Christopher A. Lazarski,et al. Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein , 2000, The Journal of experimental medicine.
[17] R. Moss,et al. Th1/Th2 cells in inflammatory disease states: therapeutic implications , 2004, Expert opinion on biological therapy.
[18] A. Banham,et al. Cutting Edge: Direct Suppression of B Cells by CD4+CD25+ Regulatory T Cells1 , 2005, The Journal of Immunology.
[19] G. Capitanio,et al. Sentinel node biopsy in breast cancer. , 2003, Breast.
[20] F. Fallarino,et al. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. , 1999, Journal of immunology.
[21] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[22] C. Berek,et al. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. , 1999, Journal of immunology.
[23] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[24] N. Smorodinsky,et al. The immune system during the precancer period: naturally-occurring tumor reactive monoclonal antibodies and urethane carcinogenesis. , 1988, Immunology letters.
[25] Andreas Radbruch,et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells , 2005, European journal of immunology.
[26] S. Ménard,et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Coussens,et al. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.
[28] Michael Karin,et al. Intracellular pattern recognition receptors in the host response , 2006, Nature.
[29] L. Benítez-Bribiesca,et al. The Role of Mast Cell Tryptase in Neoangiogenesis of Premalignant and Malignant Lesions of the Uterine Cervix , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[30] L. Tafra. Sentinel node biopsy for breast cancer. , 2002, Minerva chirurgica.
[31] D. Droz,et al. C1q deposits at the dermoepidermal junction: A marker discriminating for discoid and systemic lupus erythematosus , 1981, Journal of Clinical Immunology.
[32] L. Coussens,et al. Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.
[33] L. Coussens,et al. Immune cells as anti‐cancer therapeutic targets and tools , 2007, Journal of cellular biochemistry.
[34] G. Snell. Incompatibility reactions to tumor homotransplants with particular reference to the role of the tumor; a review. , 1957, Cancer research.
[35] F. Quismorio,et al. Circulating anti-tumor and autoantibodies in breast carcinoma: Relationship to stage and prognosis , 2005, Breast Cancer Research and Treatment.
[36] C. Berek,et al. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. , 1998, The Journal of clinical investigation.
[37] J. Pollard. Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.
[38] V. Kosma,et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. , 1992, European journal of cancer.
[39] D. Braun,et al. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. , 1998, The Journal of surgical research.
[40] L. Zitvogel,et al. Links between innate and cognate tumor immunity. , 2007, Current opinion in immunology.
[41] Noam Brown,et al. The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.
[42] Eero Pukkala,et al. Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.
[43] Y. Lee,et al. Ductular carcinoma of the breast. Serum antibodies to tumor‐associated antigens , 1979, Cancer.
[44] M. Wernicke. Quantitative morphologic assessment of immunoreactivity in regional lymph nodes of patients with carcinoma of the breast. , 1975, Surgery, gynecology & obstetrics.
[45] J. Ellner. Suppressor cells of man. , 1981, Clinical immunology reviews.
[46] D. Parker. T cell-dependent B cell activation. , 1993, Annual review of immunology.
[47] Andrew V. Nguyen,et al. Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.
[48] P. Hogarth. Fc receptors are major mediators of antibody based inflammation in autoimmunity. , 2002, Current opinion in immunology.
[49] R. Stout,et al. Antigen-specific activation of effector macrophages by IFN-gamma producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages. , 1989, Journal of immunology.
[50] E. Sánchez‐Cantalejo,et al. Correlation of Histologic Grade and Lymph Node Status with Some Histopathologic Discriminants in Breast Cancer , 1986, Tumori.
[51] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] M. Smyth,et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. , 2002, Blood.
[53] M. Smyth,et al. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.
[54] N. Funel,et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma , 2004, Journal of Clinical Pathology.
[55] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.
[56] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[57] L. Coussens,et al. The inflammatory tumor microenvironment and its impact on cancer development. , 2006, Contributions to microbiology.
[58] S. Oluwole,et al. Breast cancer in women with HIV/AIDS: Report of five cases with a review of the literature , 2005, Journal of surgical oncology.
[59] N. Kaliss. Immunological enhancement of tumor homografts in mice: a review. , 1958, Cancer research.
[60] J. Norton,et al. IL-12 induces T helper 1-directed antitumor response. , 1997, Journal of immunology.
[61] H. Hirai,et al. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. , 2003, Cancer research.
[62] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[63] Umberto Veronesi,et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.
[64] L. Happerfield,et al. Angiogenesis and inflammation in ductal carcinoma in situ of the breast , 1997, The Journal of pathology.
[65] J. Okamura,et al. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis , 1999, Gastric Cancer.
[66] H. Schreiber,et al. Immunological enhancement of primary tumor development and its prevention. , 2000, Seminars in cancer biology.
[67] R. Cardiff,et al. Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .
[68] M. Schymura,et al. Cancer incidence in New York State acquired immunodeficiency syndrome patients. , 2001, American journal of epidemiology.
[69] Susan Holmes,et al. Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer , 2005, PLoS medicine.
[70] D. Hanahan,et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.
[71] B. Fingleton,et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.
[72] D. Scadden. AIDS-related malignancies. , 1998, Current opinion in oncology.
[73] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.
[74] J. Finke,et al. Where have all the T cells gone? Mechanisms of immune evasion by tumors. , 1999, Immunology today.
[75] S. Romagnani,et al. The Th1/Th2 paradigm. , 1997, Immunology today.
[76] N. Chiorazzi,et al. Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1 , 2000, The Journal of Immunology.
[77] G. Halliday,et al. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. , 1997, The Journal of investigative dermatology.
[78] D. Ribatti,et al. Tumor vascularity and tryptase‐positive mast cells correlate with a poor prognosis in melanoma , 2003, European journal of clinical investigation.
[79] D. Bar-Sagi,et al. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.
[80] P. Telleman,et al. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. , 2001, Cancer research.
[81] T G Berger,et al. Dendritic cell-based immunotherapy. , 2003, Current topics in microbiology and immunology.
[82] L. Kemény,et al. Skin cancers after organ transplantation. , 2003, The New England journal of medicine.
[83] J. Nyhus,et al. Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. , 1999, Neoplasia.
[84] F. Shi,et al. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer , 2003, Clinical and experimental immunology.
[85] L. Adorini,et al. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation , 2002, Journal of Neuroimmunology.
[86] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[87] M. McHeyzer-Williams,et al. B cells as effectors. , 2003, Current opinion in immunology.
[88] J. Pollard,et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.
[89] F. Fallarino,et al. Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice1 , 2000, The Journal of Immunology.
[90] J. Pollard,et al. Macrophages: modulators of breast cancer progression. , 2004, Novartis Foundation symposium.
[91] A. Saraux,et al. B-cell: a logical target for treatment of rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.
[92] J. Raus,et al. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. , 1992, Anticancer research.
[93] H. Kojima,et al. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. , 2000, The European respiratory journal.
[94] A. Mantovani,et al. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.
[95] B. Fox,et al. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. , 1998, Journal of immunology.
[96] M. Kaufman,et al. Concurrent immunohistochemical staining of tumor-infiltrating lymphocytes and carcinoma-associated T (Thomsen-Friedenreich)/Tn antigens in human breast carcinoma. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[97] M. Emoto,et al. Functions of T-cell subsets and cytokines in mycobacterial infections. , 1995, The European respiratory journal. Supplement.
[98] M. Prummel,et al. Molecular cloning and characterization of genes for antibodies generated by orbital tissue-infiltrating B-cells in Graves' ophthalmopathy. , 1994, The Journal of clinical endocrinology and metabolism.
[99] J. V. Ravetch,et al. IgG Fc receptors. , 2001, Annual review of immunology.
[100] B. Griffith,et al. Solid tumors after heart transplantation: lethality of lung cancer. , 1995, The Annals of thoracic surgery.
[101] G. Opelz,et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation , 1995, The Lancet.
[102] M. Grusby,et al. Cutting Edge: STAT6-Deficient Mice Have Enhanced Tumor Immunity to Primary and Metastatic Mammary Carcinoma1 , 2000, The Journal of Immunology.
[103] A. Campbell,et al. Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients. , 1992, Cancer letters.
[104] D. Gabrilovich,et al. Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells1 , 2001, The Journal of Immunology.
[105] Makiko Kobayashi,et al. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. , 1998, Journal of immunology.
[106] V. Pistoia,et al. Relationships Between B Cell Cytokine Production in Secondary Lymphoid Follicles and Apoptosis of Germinal Center B Lymphocytes , 1995, Stem cells.
[107] E. Hersh,et al. Naturally occurring B-cell responses to breast cancer , 2003, Cancer Immunology, Immunotherapy.
[108] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[109] C. Punt,et al. Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes , 1994, Cancer Immunology, Immunotherapy.
[110] D. Page,et al. Routinely available indicators of prognosis in breast cancer , 2004, Breast Cancer Research and Treatment.
[111] L. Kaer,et al. IFN-γ–mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide , 2002 .
[112] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[113] H. David,et al. Rudolf Virchow and modern aspects of tumor pathology. , 1988, Pathology, research and practice.
[114] J. Hornaday,et al. Cancer Facts & Figures 2004 , 2004 .